Identification of an eleven-miRNA signature to predict the prognosis of endometrial cancer

References

• Siegel RL, Miller KD, Jemal A. R Cancer statistics. CA Cancer J Clin. 2020;70(1):7–30.
   Web of Science ®Google Scholar
• Binder PS, Mutch DG. Update on prognostic markers for endometrial cancer. Women’s health (London, England). 2014;10(3):277–288.
   Google Scholar
• Luo J, Chlebowski RT, Hendryx M, et al. Intentional Weight Loss and Endometrial Cancer Risk. J Clin Oncol. 2017;35(11):1189–1193.
   PubMed Web of Science ®Google Scholar
• Gildea C, Nordin A, Hirschowitz L, et al. Thirty-day postoperative mortality for endometrial cancer in England: a population-based study. BJOG. 2016;123(11):1853–1861.
   PubMed Web of Science ®Google Scholar
• Elshaikh MA, Vance S, Suri JS, et al. Improved survival endpoints with adjuvant radiation treatment in patients with high-risk early-stage endometrial cancer. Int J Radiat Oncol Biol Phys. 2014;88(2):351–356.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin. 2016;66(1):7–30.
   Web of Science ®Google Scholar
• Chen BJ, Byrne FL, Takenaka K, et al. Transcriptome landscape of long intergenic non-coding RNAs in endometrial cancer. Gynecol Oncol. 2017;147(3):654–662.
   PubMed Web of Science ®Google Scholar
• Liu H, Wan J, Chu J. Long non-coding RNAs and endometrial cancer. Biomed Pharmacothe. 2019;119:109396.
   PubMed Web of Science ®Google Scholar
• Gao L, Nie X, Zhang W, et al. Identification of long noncoding RNA RP11-89K21.1 and RP11-357H14.17 as prognostic signature of endometrial cancer via integrated bioinformatics analysis. Cancer Cell Int. 2020;20(1):268.
   PubMed Web of Science ®Google Scholar
• Li Y, Huo J, He J, et al. BTG1 inhibits malignancy as a novel prognosis signature in endometrial cancer. Cancer Cell Int. 2020;20(1):490.
   PubMed Web of Science ®Google Scholar
• Liu J, Nie S, Wu Z, et al. Exploration of a novel prognostic risk signatures and immune checkpoint molecules in endometrial cancer microenvironment. Genomics. 2020;112(5):3117–3134.
   PubMed Web of Science ®Google Scholar
• Lee YS, Dutta A. MicroRNAs in cancer. Annu Rev Pathol. 2009;4(1):199–227.
   PubMed Web of Science ®Google Scholar
• Lu TX, Rothenberg ME. MicroRNA. J Allergy Clin Immunol. 2018;141(4):1202–1207.
   PubMed Web of Science ®Google Scholar
• Carthew RW, Sontheimer EJ. Origins and Mechanisms of miRNAs and siRNAs. Cell. 2009;136(4):642–655.
   PubMed Web of Science ®Google Scholar
• Wang J, Chen J, Sen S. MicroRNA as Biomarkers and Diagnostics. J Cell Physiol. 2016;231(1):25–30.
   PubMed Web of Science ®Google Scholar
• Yang Y, Song S, Meng Q, et al. miR24-2 accelerates progression of liver cancer cells by activating Pim1 through tri-methylation of Histone H3 on the ninth lysine. J Cell Mol Med. 2020;24(5):2772–2790.
   PubMed Web of Science ®Google Scholar
• Fazio S, Berti G, Russo F, et al. The miR-28-5p Targetome Discovery Identified SREBF2 as One of the Mediators of the miR-28-5p Tumor Suppressor Activity in Prostate Cancer Cells. Cells. 2020;9(2):354.
   Web of Science ®Google Scholar
• Zheng X, Xu K, Zhu L, et al. MiR-486-5p Act as a Biomarker in endometrial cancer: promotes Cell Proliferation, Migration, Invasion by Targeting MARK1. Onco Targets Ther. 2020;13:4843–4853.
   PubMed Web of Science ®Google Scholar
• Zhang W, Chen JH, Shan T, et al. miR-137 is a tumor suppressor in endometrial cancer and is repressed by DNA hypermethylation. Lab Invest. 2018;98(11):1397–1407.
   PubMed Web of Science ®Google Scholar
• Wu A-Y, Hu Y, Cang W, et al. Suppressive effect of microRNA-449a on the NDRG1/PTEN/AKT axis regulates endometrial cancer growth and metastasis. Exp Cell Res. 2019;382(2):111468.
   PubMed Web of Science ®Google Scholar
• Liu J, Lichtenberg T, Hoadley KA, et al. An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics. Cell. 2018;(2):400–416.
   Web of Science ®Google Scholar
• Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010;26(1):139–140.
   PubMed Web of Science ®Google Scholar
• Kuleshov MV, Jones MR, Rouillard AD, et al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res. 2016;44(W1(W1):W90–W97.
   Web of Science ®Google Scholar
• Nout RA, Smit VT, Putter H, et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. Lancet (London. England). 2010;375(9717):816–823.
   Google Scholar
• Bertoli G, Cava C, Castiglioni I. MicroRNAs: new Biomarkers for Diagnosis, Prognosis, Therapy Prediction and Therapeutic Tools for Breast Cancer. Theranostics. 2015;5(10):1122–1143.
   PubMed Web of Science ®Google Scholar
• Hong H-C, Chuang CH, Huang WC, et al. A panel of eight microRNAs is a good predictive parameter for triple-negative breast cancer relapse. Theranostics. 2020;10(19):8771–8789.
   PubMed Web of Science ®Google Scholar
• Pamedytyte D, Simanaviciene V, Dauksiene D, et al. Association of MicroRNA Expression and BRAFV600E Mutation with Recurrence of Thyroid Cancer. Biomolecules. 2020;10(4):625.
   Google Scholar
• Silaghi CA, Lozovanu V, Silaghi H, et al. The Prognostic Value of MicroRNAs in Thyroid Cancers-A Systematic Review and Meta-Analysis. Cancers (Basel). 2020;12(9):2608.
   PubMed Web of Science ®Google Scholar
• Nagaraj AB, Joseph P, DiFeo A. miRNAs as prognostic and therapeutic tools in epithelial ovarian cancer. Biomark Med. 2015;9(3):241–257.
   PubMed Web of Science ®Google Scholar
• To KK, Tong CW, Wu M, et al. MicroRNAs in the prognosis and therapy of colorectal cancer: From bench to bedside. World J Gastroenterol. 2018;24(27):2949–2973.
   PubMed Web of Science ®Google Scholar
• Abreu FBD, Liu X, Tsongalis GJ. miRNA analysis in pancreatic cancer: the Dartmouth experience. Clin Chem Lab Med. 2017;55(5):755–762.
   PubMed Web of Science ®Google Scholar
• Kim JS, Chun SH, Park S, et al. Identification of Novel microRNA Prognostic Markers Using Cascaded Wx, a Neural Network-Based Framework, in Lung Adenocarcinoma Patients. Cancers (Basel). 2020;12(7):1890.
   PubMed Web of Science ®Google Scholar
• Nagy Á, Lánczky A, Menyhárt O, et al. Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets. Sci Rep. 2018;8(1):9227.
   PubMedGoogle Scholar
• Corrado G, Laquintana V, Loria R, et al. Endometrial cancer prognosis correlates with the expression of L1CAM and miR34a biomarkers. J Exp Clin Cancer Res. 2018;37(1):139.
   PubMedGoogle Scholar
• Wilczynski M, Danielska J, Domanska-Senderowska D, et al. Association of microRNA-200c expression levels with clinicopathological factors and prognosis in endometrioid endometrial cancer. Acta Obstet Gynecol Scand. 2018;97(5):560–569
   Google Scholar
• Kim JW, Mori S, Nevins JR. Myc-induced microRNAs integrate Myc-mediated cell proliferation and cell fate. Cancer Res. 2010;70(12):4820–4828.
   PubMed Web of Science ®Google Scholar
• Liu FY, Zhou SJ, Deng YL, et al. MiR-216b is involved in pathogenesis and progression of hepatocellular carcinoma through HBx-miR-216b-IGF2BP2 signaling pathway. Cell Death Dis. 2015;6(3):e1670.
   PubMedGoogle Scholar
• Yao Y, Li Q, Wang H. MiR-216b suppresses colorectal cancer proliferation, migration, and invasion by targeting SRPK1. Onco Targets Ther. 2018;11:1671–1681.
   PubMed Web of Science ®Google Scholar
• Chen Z, Han S, Huang W, et al. MicroRNA-215 suppresses cell proliferation, migration and invasion of colon cancer by repressing Yin-Yang 1. Biochem Biophys Res Commun. 2016;479(3):482–488.
   PubMed Web of Science ®Google Scholar
• Wang R, Wu Y, Huang W, et al. MicroRNA-940 Targets INPP4A or GSK3β and Activates the Wnt/β-Catenin Pathway to Regulate the Malignant Behavior of Bladder Cancer Cells. Oncol Res. 2018;26(1):145–155.
   PubMed Web of Science ®Google Scholar
• Wang Z, Tong D, Han C, et al. Blockade of miR-3614 maturation by IGF2BP3 increases TRIM25 expression and promotes breast cancer cell proliferation. EBioMedicine. 2019;41:357–369.
   PubMed Web of Science ®Google Scholar
• Conti A, Romeo SG, Cama A, et al. MiRNA expression profiling in human gliomas: upregulated miR-363 increases cell survival and proliferation. Tumour Biol. 2016;37(10):14035–14048.
   PubMedGoogle Scholar
• Yu S, Lu Z, Liu C, et al. miRNA-96 suppresses KRAS and functions as a tumor suppressor gene in pancreatic cancer. Cancer Res. 2010;70(14):6015–6025.
   PubMed Web of Science ®Google Scholar